Neutral sphingomyelinase as a target for drug design

Drug News and Perspectives

Volumn 14, Issue 10, 2001, Pages 581-590

  Wascholowski, Veit ^a   Giannis, Athanassios ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CERAMIDE; COLECALCIFEROL; CYCLOOXYGENASE 2; DESIPRAMINE; ENZYME INHIBITOR; FANTOFARONE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; MANUMYCIN A; PALMITOYL COENZYME A; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE A2; PROTEIN BCL X; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SCYPHOSTATIN; SERINE; SERINE PALMITOYLTRANSFERASE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; SPHINGOSINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; ARACHIDONIC ACID METABOLISM; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL MEMBRANE; CELL PROLIFERATION; DRUG DESIGN; DRUG TARGETING; ENZYME INHIBITION; HUMAN; INFLAMMATION; LIPID COMPOSITION; LIPID METABOLISM; NONHUMAN; SIGNAL TRANSDUCTION;

EID: 0035725279     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (117)

1. Sphingolipids - Their metabolic pathways and the pathobiochemistry of new neurodegenerative diseases
2. Signalling sphingomyelinases: Which, where, how and why
3. Physiology and pathophysiology of sphingolipid metabolism and signaling
4. Sphingosine 1-phosphate: A ligand for the EDG-1 family of G-protein-coupled receptors
5. Modulation of the ceramide level, a novel therapeutic concept
6. Ceramide and inflammation
7. Mice lacking the tumour necrosis factor receptor I are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes
8. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection
9. Role of ceramide in lipopolysaccharide (LPS)-induced signaling
10. Cytokine regulation of eicosanoid generation
11. 2 in pulmonary A549 cells does not involve activation of NF-kappaB
12. Cyclooxygenase-2: Regulation and relevance in inflammation
13. Cyclooxygenases 1 and 2
14. Endothelial cell inflammatory responses to tumor necrosis factor alpha
15. Interleukin-10 and interleukin-13 inhibit proinflammatory cytokine-induced ceramide production through the activation of phosphatidylinositol 3-kinase
16. 2 is phosphorylated and activated by MAP kinase
17. Advances in the signal transduction of ceramide and related sphingolipids
18. 2 by the p55 TNF receptor occurs independently of FAN
19. The biochemistry of apoptosis
20. Apoptosis
21. Morphologic and biochemical hallmarks of apoptosis
22. FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase
23. CD40 signals apoptosis through FAN-regulated activation of the sphingomyelin-ceramide pathway
24. Role of c-jun expression increased by heat shock- and ceramide-activated caspase-3 in HL-60 cell apoptosis. Possible involvement of ceramide in heat shock-induced apoptosis
25. Activation of a nuclear sphingomyelinase in radiation-induced apoptosis
26. Ceramide formation leads to caspase-3 activation during hypoxic PC12 cell death
27. Killing cancer cells by polydrug elevation of ceramide levels
28. Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals
29. CD28 signals through acidic sphingomyelinase
30. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling
31. TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase
32. Mechanisms by which short-chain ceramides cause apoptosis
33. Induction of apoptosis by synthetic ceramide analogues in the human keratinocyte cell line HaCaT
34. Ceramide generation in nitric oxide-induced apoptosis. Activation of magnesium-dependent neutral sphingomyelinase via caspase-3
35. Positive feedback control of neutral sphingomyelinase activity by ceramide
36. Protein kinase B (c-Akt): A multifunctional mediator of phosphatidylinositol 3-kinase activation
37. Ceramide inhibits protein kinase B/Akt by promoting dephosphorylation of serine 473
38. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)
39. Mitochondria as the central control point of apoptosis
40. Apoptosis-inducing factor (AIF): A ubiquitous mitochondrial oxidoreductase involved in apoptosis
41. Cell suicide for beginners
42. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor
43. Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress
44. Possible involvement of cytochrome c release and sequential activation of caspases in ceramide-induced apoptosis in SK-N-MC cells
45. Bcl-2 family: Life-or-death switch
46. The little devil of death
47. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC
48. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
49. Ceramide activates the stress-activated protein kinases
50. Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of jun N-terminal kinase/p38 kinases and GADD153
51. Ceramide directly activates protein kinase C to regulate a stress-activated protein kinase signaling complex
52. Stress signals for apoptosis: Ceramide and c-jun kinase
53. Induction of apoptosis by the transcription factor c-jun
54. Neuropharmacologic aspects of apoptosis: Significance for neurodegenerative diseases
55. Role of sphingolipid-mediated cell death in neurodegenerative diseases
56. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy
57. Protecting the female germ line from cancer therapy
58. Induction apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer
59. Effect of ceramide on intracellular glutathione determines apoptotic or necrotic cell death of JB6 tumor cells
60. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis
61. Ceramide interaction with the respiratory chain of heart mitochondria
62. Calcium-independent activation of endothelial nitric oxide synthase by ceramide
63. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate
64. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: Protection by fibroblast growth factor and sphingomyelinase deficiency
65. Non-enzymatic triggering of the ceramide signalling cascade by solar UVA radiation
66. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis
67. 2 and facilitates its membrane docking and arachidonic acid release
68. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A. block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells
69. Accumulation of glucosylceramides in multidrug-resistant cancer cells
70. Tamoxifen retards glycosphingolipid metabolism in human cancer cells
71. SDZ PSC 833, the cyclosporine A analogue and multidrug resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells
72. Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells
73. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells
74. Cloned mammalian neutral sphingomyelinase: Functions in sphingolipid signaling?
75. Molecular cloning, characterization, and expression of a novel human neutral sphingomyelinase
76. 2+-dependent neutral sphingomyelinase
77. Identification of multiple forms of membrane-associated neutral sphingomyelinase in bovine brain
78. Purification and characterisation of a magnesium-dependent neutral sphingomyelinase from bovine brain
79. Purification and characterization of a membrane bound neutral pH optimum magnesium-dependent and phosphatidylserine-stimulated sphingomyelinase from rat brain
80. Identification of a distinct pool of sphingomyelin involved in the sphingomyelin cycle
81. Comparative study of the metabolic pools of sphingomyelin and phosphatidylcholine sensitive to tumor necrosis factor
82. Expression of neutral sphingomyelinase identifies a distinct pool of sphingomyelin involved in apoptosis
83. Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor alpha
84. Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione
85. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death
86. Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling
87. TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase
88. Regulation of ceramide production and apoptosis
89. Enzymic hydrolysis of sphingomyelin by rat liver
90. Occurrence of two molecular forms of human acid sphingomyelinase
91. Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labelling of P-glycoprotein
92. Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha/cycloheximide-induced cerebral endothelial cell death
93. Structural elucidation of scyphostatin, an inhibitor of membrane-bound neutral sphingomyelinase
94. 2+-stimulated sphingomyelinase in fetal bovine serum
95. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development
96. A novel magnesium-independent neutral sphingomyelinase associated with rat central nervous system myelin
97. 3-induced HL-60 cell differentiation
98. The subcellular localization of neutral sphingomyelinase in rat liver
99. The presence of sphingomyelin- and ceramide-cleaving enzymes in the small intestinal tract
100. Characterization of the neutral pH-optimum sphingomyelinase from rat brain: Inhibition by copper II and ganglioside GM3
101. Biological activities of scyphostatin, a neutral sphingomyelinase inhibitor from a discomycete, Trichopeziza mollissima
102. Synthesis of the first selective irreversible inhibitors of neutral Sphingomyelinase
103. Manumycin A and its analogues are irreversible inhibitors of neutral sphingomyelinase
104. Alkaline sphingomyelinase activity in rat gastrointestinal tract: Distribution and characteristics
105. Identification of an alkaline sphingomyelinase activity in human bile
106. Scyphostatin, a neutral sphingomyelinase inhibitor from a discomycete, Trichopezzia mollissima
107. Alutenusin, a specific neutral sphingomyelinase inhibitor, produced by Penicillium sp. FO-7436
108. Macquarimicin A inhibits membrane-bound neutral sphingomyelinase from rat brain
109. F-11334s, new inhibitors of membrane-bound neutral sphingomyelinase
110. Charged with meaning: The structure and mechanism of phosphoprotein phosphotases
111. Synthesis of the first selective irreversible inhibitor of neutral sphingomyelinase
112. Synthesis and biochemical investigation of scyphostatin analogues as inhibitors of neutral sphingomyelinase
113. Stoffwechselprodukte von mikroorganismen
114. Identification of Ras farnesyltransferase inhibitors by microbial screening
115. Inhibition of corneal inflammation by the topical use of Ras farnesyltransferase inhibitors: Selective inhibition of macrophage localization